January 5th 2023
By Joe Bullock
I’ve heard the phrase, “don’t waste your cancer,” as a way to encourage survivors to tell their stories and donate to nonprofits.
January 4th 2023
By Ngozi Ejedimu
Now that I’m six years out of my breast cancer treatment, people assume that I’m better and lack empathy. However, my anxiety is still high.
By Laura Yeager
My local cancer wellness center offered a singing bowls session, which I found incredibly relaxing.
January 3rd 2023
By Sailaja Darisipudi
Through a survey on social media, CURE® collected responses on what terms people prefer when describing their cancer experiences. Some people who have experienced cancer explain why they have embraced the terms "thriver" and "warrior."
January 2nd 2023
CURE® surveyed its audience to see which terms they prefer to use when describing their cancer experiences. Some people who have experienced cancer explain their mixed feelings with the commonly used terms “patient” and “survivor.”
December 22nd 2022
A childhood cancer survivor now works raising funds for Children’s Hospital of Philadelphia, the same hospital where she received treatment for Ewing sarcoma at 12 years old.
December 21st 2022
By Kristie L. Kahl
As part of its Speaking Out video series, CURE® spoke with Michael J. Rovito, on behalf of the Testicular Cancer Foundation, about survivorship.
Treat yourself without the guilt! Here are three delicious — and most importantly nutritious — desserts to try at home when you are craving something sweet.
December 20th 2022
By Dr. Carolyn Bhakta
After undergoing a mastectomy, women can either proceed with reconstruction or "go flat," but one expert says that the correct decision is what’s best for the patient.
December 15th 2022
By Brielle Benyon
In honor of CURE®’s 20th anniversary, here is a roundup of some of the major advancements in the world of cancer care, according to experts, patients and advocates.
New Diagnosis Codes Improve Timely Access Inflammatory Breast Cancer Care
Standing Up to Cancer is Far More Than Slogans
Perioperative Immunotherapy ‘Is The Revolution’ in NSCLC
FDA Accepts New Drug Application for Relacorilant in Ovarian Cancer